Amolyt Raises $80M to Develop AZP-3601 for Hypoparathyroidism

Amolyt Raises $80M to Develop AZP-3601 for Hypoparathyroidism

306545

Amolyt Raises $80M to Develop AZP-3601 for Hypoparathyroidism

Amolyt Pharma has raised $80 million in financing that will support the clinical development of AZP-3601, its experimental therapy for hypoparathyroidism. Hypoparathyroidism is caused by abnormally low levels of the parathyroid hormone (PTH), leading to low vitamin D and calcium levels, as well as high phosphorus levels in the blood. Current therapies frequently fail to control calcium blood levels and to prevent excessive calcium loss in the urine, which increases the risk of chronic kidney…

You must be logged in to read/download the full post.